Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine + enalapril
- Development stage
- Unknown
- Lead developer
- Novartis and Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of cyclosporine, an immunosuppressant that works as a calcineurin inhibitor, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor. This combination is used in renal transplant recipients to manage hypertension while providing immunosuppression. Clinical studies have shown that this combination provides better blood pressure control than either drug alone and may prevent the enalapril-induced initial rise in serum creatinine.
02
Targets
ACE (Angiotensin Converting Enzyme)CN (Calcineurin)
Beyond the preview
Go deeper on cyclosporine + enalapril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine + enalapril.